Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.

Saved in:
Bibliographic Details
Title: Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.
Authors: Cook LB; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK.; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., O'Dell G; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Vourvou E; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Palanicawandar R; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Marks S; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Milojkovic D; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK.; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Apperley JF; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK.; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Loaiza S; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Claudiani S; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Bua M; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Hockings C; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Macdonald D; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK.; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Chaidos A; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK.; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Pavlu J; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Cooper N; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK.; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Fidler S; Section of Virology, Faculty of Medicine, Department of Infectious Diseases, Imperial College London, London, UK., Randell P; Department of Infection and Immunity, North West London Pathology, London, UK., Innes AJ; Centre for Haematology, Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, UK. a.innes@imperial.ac.uk.; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK. a.innes@imperial.ac.uk.
Source: Nature communications [Nat Commun] 2022 Nov 14; Vol. 13 (1), pp. 6922. Date of Electronic Publication: 2022 Nov 14.
Publication Type: Observational Study; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-022-34657-z